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ABSTRACT (249/250)
Objective
To assess long-term safety in a US cohort of rheumatoid arthritis (RA) patients treated with 
adalimumab in real-world clinical care settings.
Methods
This observational study analyzed the long-term incidence of safety outcomes among RA 
patients initiating adalimumab using data from the Corrona RA registry. Patients were adults 
(≥18 years) who initiated adalimumab treatment between January 2008 and June 2017, and 
who had at least 1 follow-up visit.
Results
In total, 2798 adalimumab initiators were available for analysis, with a mean age of 54.5 years, 
77% female, and mean duration of disease of 8.3 years. Nearly half (48%) were biologic naïve, 
and 9% were using prednisone ≥10 mg at adalimumab initiation. The incidence rates per 100 
person-years for serious infections, congestive heart failure requiring hospitalization, 
malignancy (excluding nonmelanoma skin cancer), and all-cause mortality were 1.86, 0.15, 0.64, 
and 0.33, respectively. The incidence of serious infections was higher in the first year of therapy 
(3.44 [95% confidence interval: 2.45–4.84]) than subsequent years, while other measured AEs 
did not vary substantially by duration of exposure. The median time to adalimumab 
discontinuation was 11 months, while the median time to first serious infection among those 
experiencing a serious infection event was 12 months. 
Conclusion
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Analysis of long-term data from this prospective real-world registry demonstrated a safety 
profile consistent with previous studies in patients with RA. This analysis did not identify any 
new safety signals associated with adalimumab treatment and provides valuable guidance for 
physicians prescribing adalimumab for extended periods of time. 
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Rheumatoid arthritis (RA) is a complex immune-mediated inflammatory disease, which, if not 
treated effectively, can cause significant pain and progressive joint damage leading to disability 
and a reduced quality of life (1,2). When compared with the general population, RA is 
associated with increased morbidity due to complications and comorbidities such as serious 
infections, cardiovascular (CV) disease and certain cancers (3-5). Higher mortality rates have 
also been reported (3,5). Inhibition of tumor necrosis factor (TNF), a key component of the 
inflammatory mechanism associated with many immune-mediated diseases, has been shown to 
reduce RA disease activity and improve clinical, radiographic, and functional outcomes (6,7).
TNF inhibitors (TNFi) have been associated with a reduced risk of CV disease in patients with RA 
(8,9); however, some uncertainty remains on the increased risk of infections and the increased 
potential for malignancy and other adverse events (AE) in patients treated with TNFi. Prior 
studies have reported an increased risk of serious infections and malignancies, particularly 
lymphoma, in psoriasis patients treated with TNFi, while other more recent studies have not 
identified similar significantly increased risks among patients treated with TNFi (10-18). As TNF 
is an important component of the human immune system and has a role in tumor growth 
mediation, the link between its inhibition and an increase in the frequency of serious infections 
or malignancies deserves more investigation (19).
To date, more than 20 years after the introduction of TNFis, the safety of biologics, such as 
adalimumab (ADA), has been established through both randomized controlled clinical trials and 
registry-based European observational studies (17,18,20-22). A large cross-indication (including 
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RA, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s 
disease) analysis of long-term safety based on almost 30,000 patients treated with ADA in 
global clinical trials and open-label extension studies did not identify any new safety signals, 
although individual differences between the disease populations did exist (17,18). Additionally, 
in these studies the mortality rate for most indications was below what would be expected in 
an age- and gender-adjusted population (17,18). However, the patient populations from 
randomized clinical trials and open-label extension studies may not be reflective of a real-world 
population of RA patients in the US. Comparisons between different registry-based studies are 
also challenging due to differences in design, follow-up assessments, and other variables 
assessed within each registry, which may result in heterogeneity between studies (23). For 
example, the percentage of patients with a high Disease Activity Score has been shown to vary 
between registries, with patients in the Corrona registry having lower disease activity and 
higher functional status (23,24). Differences in healthcare delivery systems and baseline patient 
characteristics between European and US populations may result in differences in the 
underlying risk of certain AEs, highlighting the need to establish the safety profile of TNFi in 
both of these populations. 
The long-term incidence of AEs among ADA users in real-world clinical settings has not been 
well documented in the United States. In a recent US study, approximately half of biologic-naive 
RA patients stated their primary unwillingness to initiate treatment with a biologic was due to 
fear/concern about side effects, highlighting the need to clarify the safety of biologics, such as 
ADA, in US real-world practice (25). The objective of our study was therefore to build on the 
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existing knowledge base on the safety of TNFis through the evaluation of the risk of AEs in 
relation to duration of ADA exposure in a US-based population. This will complement ongoing 
long-term clinical trial safety analyses and further test the hypothesis that the real-world safety 
profile of ADA is consistent with that previously demonstrated by randomized controlled clinical 
trial analyses as well as ex-US RA registries.
MATERIALS AND METHODS
Study design
This was a retrospective analysis of the US Corrona RA Registry, a prospective observational 
cohort of RA patients initiated in 2001 (26), which contains data on nearly 50,000 patients 
across 40 states, covering approximately 373,000 visits and 173,000 patient-years of follow-up. 
Data are collected from both patients and their treating rheumatologists, who gather 
information on disease duration, prognosis, disease severity and activity, comorbidities, use of 
medications, and patient-reported outcome (PRO) data. Participating rheumatologists also 
actively assess for the occurrence of AEs at each registry follow-up visit. Follow-up assessments 
are requested as often as approximately every 6 months and completed during routine clinical 
encounters. 
Study population
Patients were included in this analysis if they were adults (≥18 years of age), initiated ADA as 
therapy for a clinical diagnosis of RA between 01 January 2008 and 01 June 2017, and were 
enrolled in the US Corrona RA Registry. Patients were also required to have at least 1 follow-up 
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visit post drug initiation. Patients with RA onset prior to 16 years of age were excluded from the 
study.
Ethics
All patients provided written informed consent prior to registry participation. Institutional 
review board (IRB) approvals for this study were obtained from a central IRB (New England 
Independent Review Board, NEIRB No. 02-021) for private practice sites and local IRBs of 
participating academic sites.
Exposure
The date on which each patient initiated ADA therapy was defined as their “index date” and 
served as the starting point for the measurement of both the time to first AE and the incidence 
of the AE over time.
Outcomes and covariates
The safety outcomes assessed in this analysis were physician-reported serious infections (eg, 
infections requiring hospitalization or intravenous antibiotics), malignancies (excluding 
nonmelanoma skin cancer), congestive heart failure (CHF) that required hospitalization, 
tuberculosis (TB) with a focus on active TB, and drug-induced systemic lupus erythematosus 
(SLE). All-cause mortality was also assessed. Outcomes were assessed by both time from ADA 
initiation to the first occurrence of a specific AE, and the frequency, or “incidence,” of each 
specific AE over time. Measurement of these outcomes continued until either the first 
Page 8 of 33
Th
is
 a
cc
ep
te
d 
ar
tic
le
 is
 p
ro
te
ct
ed
 b
y 
co
py
rig
ht
. A
ll 
rig
ht
s r
es
er
ve
d.A
cc
ep
te
d 
A
rt
ic
le
 of Rheumatology
The Journal on September 16, 2019 - Published by www.jrheum.orgDownloaded from 
9
occurrence of the specific AE, or, for incidence of the specific AE over time, until 90 days 
following discontinuation of ADA or the patient’s last Corrona visit (whichever occurred first), at 
which point the patient was censored. For malignancy and mortality, all events occurring during 
follow-up were included regardless of ADA continuation or discontinuation.
The Corrona registry uses an established system for the validation of physician-reported AEs. In 
brief, treating physicians complete “Targeted Adverse Event” questionnaires to record serious 
AEs. These questionnaires, alongside supporting documents appropriate to the event (eg, 
hospitalization records, pathology reports), are submitted to Corrona for validation. A subset of 
questionnaires is also triaged for expert adjudication. This methodology has been supported by 
previous validation studies, which found positive predictive values of Targeted Adverse Event 
forms to be 96% for CV events (27), 86% for malignancies (28), and 71% for serious infectious 
events (29).
Analysis
Demographic and disease characteristics, including prior treatment history, of all patients at the 
time of their ADA therapy initiation were recorded. Percentages were used to describe 
categorical variables while means and standard deviations (SD) were used to describe 
continuous variables. In cases of highly skewed distributions, medians and interquartile ranges 
were used to describe continuous variables. 
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The analysis of time from ADA initiation to the first occurrence of a specific AE was analyzed as 
‘incident events.’ For each specific AE, only patients without a history of that AE prior to or at 
the time of ADA initiation were followed for the occurrence of the AE. 
Incidence rates (IR) and 95% confidence intervals (CIs) are reported per 100 person-years, 
assuming a Poisson distribution. Time to the first event for particular events, including time to 
discontinuation, time to serious infection, and time to malignancy, was evaluated using Kaplan-
Meier curves. Median (95% CIs) time to first event was calculated as well as the proportion of 
patients that did not have an event at 6, 12, 24, 36, 48, 60, 72 and 84 months after ADA 
initiation. The standardized mortality ratio (SMR) was calculated based on recent Centers for 
Disease Control and Prevention mortality data (30).
RESULTS
Study population at ADA initiation
In total, 2798 real-world patients who had initiated ADA therapy were available for analysis. 
Patient, disease, and prior treatment characteristics of these patients at time of ADA initiation 
are presented in Table 1. The mean age of these patients, who were predominantly female 
(77%), was 54.5 years (SD: 12.3 years), with a mean body mass index (BMI) of 30.4 (SD: 7.5) and 
approximately half of patients (52%) had never smoked. The mean (SD) duration of disease was 
8.3 (9) years, and mean CDAI was 20.4 (14) with 39% of patients in the high disease activity 
category. Approximately half (48%) were biologic naïve, and 9% were treated with ≥10 mg 
prednisone daily. The majority of patients (60%) were receiving concomitant methotrexate at 
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ADA initiation. 
Duration of ADA exposure during the assessment period
Overall, the majority of patients (84%) received ADA therapy for <3 years (Table 1). The median 
time from ADA initiation to last visit on ADA therapy was 11 (95% CI: 4–25) months. The 
proportion of patients remaining on ADA therapy at 6 and 12 months after initiation was 70% 
and 56%, respectively. In the subset of patients that were biologic-naïve at ADA initiation, the 
median time from ADA initiation to last visit on ADA therapy was 13 (95% CI: 6–29) months, 
with 78% and 62% remaining on ADA at 6 and 12 months, respectively.
The probability of patients within the analysis remaining on ADA over time is presented as a 
time to discontinuation from ADA in Figure 1. The 3 most commonly reported reasons for 
discontinuing ADA treatment among the overall population included failure to maintain initial 
response (27%), inadequate initial response (16%), and minor side effect (14%); serious side 
effects accounted for 6% of reported reasons for discontinuation (data not shown). Similar 
frequencies of reasons for discontinuation were observed among the bio-naïve population. 
Incidence of events during ADA exposure 
The IR per 100 person-years of ADA exposure was 1.86 (95% CI: 1.50–2.31) for serious 
infections, 0.15 (0.07–0.31) for CHF requiring hospitalization, 0.64 (0.50–0.84) for malignancy 
(excluding nonmelanoma skin cancers), and 0.33 (0.24–0.48) for all-cause mortality (Table 2). 
No cases of TB were reported during follow-up. The IR per 100 person-years of ADA exposure 
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for AEs included in this study (excluding malignancy and mortality) leading to ADA 
discontinuation was 0.73 (0.52–1.03). 
The incidence of events by duration of ADA exposure categories (≤1 year, >1 to 3 years, >3 to 5 
years, >5 years) are presented in Figure 2. The incidence of serious infections was higher in the 
first year of therapy (3.44 [95% CI: 2.45–4.84]) than subsequent years, while other AEs did not 
vary by duration of exposure. 
Time to first occurrence of adverse events of interest
Median times to first serious infection and malignancy among those experiencing each 
respective event were 12 (95% CI: 7–26) months and 34 (16–56) months, respectively. The 
proportion of patients not having a first occurrence of serious infection and malignancy at 6 
months was 98.4% and 99.7%, respectively. This remained largely unchanged at 12 months, at 
which 97.5% and 99.4% of patients had not had an occurrence of serious infection or 
malignancy. Throughout the remainder of the evaluation period, the large majority of patients 
did not have an occurrence of serious infection or malignancy at 24, 36, 48, 60, 72 or 84 months 
(Suppl Table 2). Kaplan-Meier curves for the probability of not having a serious infection or 
having a malignancy event are presented in Figure 3 and Figure 4, respectively.
Standardized mortality ratio
The age-gender adjusted SMR comparing the observed and expected number of deaths was 
0.50 ± 0.32. The SMR reveals that there were an expected 62 mortalities within the ADA 
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initiating population compared to only 31 deaths observed (data not shown). 
DISCUSSION 
With an increasing number of physicians prescribing disease modifying anti-rheumatic 
medications for long-term, chronic use, knowledge of the long-term safety profiles of such 
medications is critical in guiding providers in prescribing strategies which minimize the risk of 
serious AEs for their patients. This retrospective analysis of a real-world US database of RA 
patients treated with ADA immunotherapy is consistent with the previously established safety 
profile through RCTs, open-label extension studies and European RA registries. 
A recent update of global long-term clinical trial safety data in adult patients treated with ADA 
for multiple indications (predominately RA studies), which included 29,987 patients with 56,951 
patient-years of exposure, identified serious infections as the most frequent AE, with an IR of 
4.6 events per 100 patient-years (18). Our study found a lower IR per 100 person-years for 
serious infections, which was higher during the first year of exposure (3.44 [95% CI: 2.45-4.84]) 
than subsequent years. Previous studies have also shown the risk of infection to be higher 
earlier in treatment compared with later in treatment (31). It may be the case that these AEs 
were more strictly reported in the clinical trials, as compared with the Corrona registry, 
although given the serious nature of these AEs, this seems unlikely. Patients in Corrona may 
have lower levels of disease activity compared to patients in the RCTs; previous studies have 
shown that increased RA disease activity is associated with an increased risk for serious 
infections (24,32,33). Differences in the methodology used for the calculation of AE IRs may 
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also help explain the differences in the observed rates; compared to the present study which 
captured AEs at the patient level, the global long-term clinical trials study captured AEs at the 
event level, with multiple AEs of the same type within an individual reflected in the IRs. The 
global clinical trial analysis reported a lower number of deaths in RA patients treated with ADA 
(SMR of 0.74) than would be expected in an age- and gender- adjusted population (18), which 
was directionally similar to the SMR observed in this real-world analysis. For both analyses, 
underlying explanations for this result are not immediately clear. 
Comparison of the Corrona registry findings with those from other real-world databases also 
reveals variations in outcomes across these analyses. The British Society for Rheumatology 
Biologics Register for Rheumatoid Arthritis (BSRBR-RA) reported that no TNFi was associated 
with a statistically higher risk of serious infection than any other TNFi among a total of 19,282 
patients contributing 46,771 patient-years of follow-up. BSRBR-RA reported an IR for serious 
infection of 5.42 per 100 patient-years among 7,818 patients initiating ADA which was higher 
than the first year incidence rates of serious infection reported for ADA exposed patients in our 
study (IR=3.44) (22). The IR for malignancy during a median follow-up of 3.5 years per patient in 
a BSRBR-RA cohort exposed to TNFi was more similar, although still slightly higher, than that 
observed in the present study (0.77 vs. 0.64, respectively) (21). During a total of 3 years follow-
up, the Anti-Rheumatic Therapy in Sweden (ARTIS) biologics register reported an IR for 
mortality of 1.4 per 100 person-years after exposure to ADA. In both studies, the IRs observed 
may be higher than that reported in our analysis due to differences in median follow-up time 
(20).  Additionally, patients in Europe often have more restricted access to biologics and thus 
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have higher levels of disease activity, greater use of prednisone and higher levels of disability 
prior to biologic initiation, all of which influence the risk of infection (24,34). Prevalence of 
clinical characteristics (eg, smoking) and comorbidities (eg, obesity) also varies between US and 
European registries, which may reflect the way comorbidity data were captured as well as 
general cultural differences between countries; differences in comorbidity profiles could create 
differences in the incidence rates of AEs (23,24). 
Comparing safety outcomes for ADA in US clinical practice using data from a large, nationwide 
cohort of patients with RA is a vital strength of this study. Due to payer and regulatory 
differences, patient characteristics and access to biologic drugs can vary substantially between 
countries. Therefore, it is essential to obtain representative clinical evidence directly relevant to 
practicing rheumatologists in the United States. A previous study showed that Medicare 
beneficiaries who were enrolled in Corrona share similar demographic and clinical 
characteristics with Medicare beneficiaries with claims for RA or visits to a rheumatology 
specialist who were not enrolled, thus suggesting that the results presented here may be 
generalizable to the broader RA population in the United States (35). The relative similarity of 
the AE findings of our analysis compared with prior clinical trials and other observational 
registry studies is reassuring, yet also highlights the importance of continuing to assess these 
outcomes over longer periods of time, and in more diverse populations.
This study also has several limitations. First, ADA exposure time was limited for some patients. 
In total, 50% of patients used ADA for 1 year or less and only 16% of patients were exposed for 
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3 years or more. While serious infection event rates tend to be highest during the first 6–12 
months of TNFi exposure (36,37), the limited number of patients in our study with longer-term 
ADA exposure may not have allowed us to fully characterize the rates of serious infection as 
well as other AEs such as malignancies due to the relative infrequency and longer-term onset of 
these AEs. There is an inability to determine with certainty if ADA exposure had an impact on 
the development of the AEs measured, particularly, those AEs occurring after drug 
discontinuation or conditions which typically take many years to develop (eg, malignancy). We 
did not account for subsequent therapies initiated after adalimumab discontinuation and their 
potential impact on the occurrence of AEs observed in this study. The SMR among this 
population was low, which suggests the possibility of under-ascertainment of events within the 
Corrona registry; however, serious events are less likely to be underreported and a low SMR 
was also found in the ESPRIT study which evaluated the long-term safety and effectiveness of 
ADA in the treatment of psoriasis and in studies evaluating the long-term safety of ADA across 
multiple indications (15,17,18). Finally, the precision with which ADA discontinuation is 
measured in the Corrona registry may have resulted in misclassified exposure time. The date of 
discontinuation was recorded at the time of physician visit, however, there may be challenges 
with recall bias if the discontinuation is not well documented in the physician’s clinical notes. 
This analysis of targeted data from the prospective Corrona real-world RA registry 
demonstrated ADA to have a safety profile consistent with previous studies and did not identify 
any new safety signals with long-term ADA treatment. Therefore, with the addition of these 
real-world data in a large sample of US RA patients, the previously understood benefit-risk 
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profile of ADA for the treatment of RA remains unchanged. This confirmation of existing 
knowledge may reassure providers who are initiating and monitoring ADA in their patients.
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FIGURE LEGENDS
Figure 1. Probability of remaining on adalimumab treatment. CI, confidence interval.
Figure 2. Incidence of events by duration of adalimumab exposure. Error bars indicate 95% 
confidence intervals. aSerious infections included those that led to hospitalization or IV 
antibiotics. bMalignancy excluded nonmelanoma skin cancer. CHF, congestive heart failure; IV, 
intravenous.
Figure 3. Probability of not having a serious infection. CI, confidence interval.
Figure 4. Probability of not having a malignancy event. CI, confidence interval.
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Table 1. Patient, disease, and prior treatment characteristics at ADA initiation
ADA initiators
(n=2798)
Patient characteristics
Age in years, mean (SD) 54.5 (12.3)
Female 2167 (77)
Race, n (%)  
    Indigenous American 19 (1)
    White Caucasian 2477 (89)
    African American 200 (7)
    Asian 30 (1)
    Othera 72 (3)
BMI, n 2784
    Mean (SD) 30.4 (7.5)
BMI categorized, n (%)  
    Underweight/normal (<25) 683 (25)
    Overweight (25≤BMI≥30) 868 (31)
    Obese (30<BMI≤35) 576 (21)
    Extremely obese (<35) 657 (24)
Smoking status, n (%)  
  Never smoker 1441 (52)
  Previous smoker 767 (27)
  Current smoker 568 (20)
Histories of comorbidities, n (%)  
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   Malignancy (excluding NMSC) 133 (5)
   Congestive heart failure 17 (1)
   Serious infections* 127 (5)
   Cardiovascular disease** 959 (34)
Disease characteristics
Duration of disease, mean (SD) 8.3 (9)
Swollen joint count (0–28) median (IQR) 4 (1, 8)
Tender joint count (0–28) median (IQR) 5 (1, 10)
Patient pain (0–100) median (IQR) 50 (24, 70)
Patient global assessment (0–100) median (IQR) 49 [20, 68)
Physician global assessment (0–100) median (IQR) 35 (17, 50)
CDAI, mean (SD) 20.4 (14)
HAQ, mean (SD) 0.50 (0.50)
DAS28, mean (SD) 4.2 (1.6)
Treatment characteristics
ADA exposure time  
   ≤1 year 1398 (50)
   >1–3 years 945 (34)
   >3–5 years 290 (10)
   >5–7 years 114 (4)
   >7 years 51 (2)
Prednisone use, n (%)
  No prednisone use 2004 (72)
  Prednisone dose <10 mg 525 (19)
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  Prednisone dose ≥10 mg 242 (9)
Prior biologics used (median IQR) 1 (0, 1)
   Naïve 1337 (48)
   1 previous biologic 992 (35)
   2 previous biologics 321 (11)
   3 or more previous biologics 148 (5)
Prior cDMARDs used (median IQR) 2 (1, 2)
   Naïve 131 (5)
   1 previous cDMARD 1254 (45)
   2 or more previous cDMARD 1413 (51)
Concomitant MTX, alone or in combination, n (%) 1678 (60)
a “Other” category includes Pacific Islander, Unknown, Mixed Race, and (originally) Other. *History of serious 
infections include those infections that lead to hospitalization or intravenous antibiotics, including joint/bursa, 
cellulitis, sinusitis, diverticulitis, sepsis, pneumonia bronchitis, gastroenteritis, meningitis, urinary tract infection, 
upper respiratory infection, or other specified infections. **History of cardiovascular (CV) disease includes 
hypertension, coronary artery disease, cardiac revascularization procedure (coronary artery bypass grafting, stent, 
angioplasty), ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, congestive 
heart failure, unstable angina, stroke, transient ischemic attack (TIA), other CV events, deep vein thrombosis, 
peripheral artery disease, pulmonary embolism, peripheral arterial thrombosis, urgent peripheral 
revascularization, peripheral ischemia/gangrene, hyperlipidemia, and carotid artery disease. ADA, adalimumab; 
BMI, body mass index; CDAI, Clinical Disease Activity Index; cDMARD, conventional disease-modifying 
antirheumatic drug; DAS28, Disease Activity Score in 28 joints; HAQ, Health Assessment Questionnaire; IQR, 
interquartile range; MTX, methotrexate; NMSC, nonmelanoma skin cancer, SD, standard deviation.
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Table 2. Incidence of AEsa among ADA initiators.
All ADA initiators
Variable Patients with ≥1 
event, n
Follow-up time, 
PYs
Rate, events/100 PYs
(95% CI)
Serious infectionsb 83 4452 1.86 (1.50–2.31)
Tuberculosis 0 4751 0 (N/A–N/A)
CHF requiring hospitalization 7 4728 0.15 (0.07–0.31)
Drug-induced SLE 2 4750 0.04 (0.01–0.17)
Any AE listed above leading to 
discontinuation of ADAc 
33 4494 0.73 (0.52–1.03) 
Malignancyd 56e 8691 0.64 (0.50–0.84) 
Mortality 31 9268 0.33 (0.24–0.48)
aAmong patients without a history of and who were not experiencing the particular event at the time of ADA 
initiation. bSerious infections included those that led to hospitalization or intravenous antibiotics, including 
joint/bursa, cellulitis, sinusitis, diverticulitis, sepsis, pneumonia, bronchitis, gastroenteritis, meningitis, urinary tract 
infection, upper respiratory infection, or other specified infections. Among those with serious infections, we 
calculated the number of opportunistic infections, including histoplasmosis, coccidioidomycosis, pneumocystosis, 
listeria, herpes zoster/varicella-zoster virus and active tuberculosis. Aspergillosis, blastomycosis, legionella, and 
candidiasis information were not specifically collected. cExcludes malignancy as all person-time time was used to 
assess rate of malignancy, regardless of ADA continuation or discontinuation during follow-up. dExcluding 
nonmelanoma skin cancer. eIncludes solid tumors (n=40), melanoma (n=8), lymphoma (n=6), and other blood 
cancers (n=2).  ADA, adalimumab; AE, adverse event; CHF, congestive heart failure; CI, confidence interval; N/A, 
not applicable; PY, person-year; SLE, systemic lupus erythematosus.
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Figure 1. Probability of remaining on adalimumab treatment 
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Figure 2. Incidence of events by duration of adalimumab exposure 
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Figure 3. Probability of not having a serious infection.
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Figure 4. Probability of not having a malignancy event .
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